About RexahnClinical DevelopmentTechbologiesPatientsInvestor RelationsMedia Center

 

 

 

 


About Rexahn
Fact Sheet

Annual Report
Corporate Governance

FAQ's
SEC Filings

Stock Quote

 


Warning: fopen() [function.fopen]: URL file-access is disabled in the server configuration in C:\Inetpub\wwwroot\stock.php on line 3

Warning: fopen(http://finance.yahoo.com/d/quotes.csv?s=RNN&f=sl1d1t1c1ohgvmnxt7p2baa2a5b6pp&e=.csv) [function.fopen]: failed to open stream: no suitable wrapper could be found in C:\Inetpub\wwwroot\stock.php on line 3

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in C:\Inetpub\wwwroot\stock.php on line 4
 Stock Quote
 
Last Trade: at
 Last Price :  $
 Change : ()
 Volume :  0
 Day High :  $
 Day Low :  $
 Open :  $
 Prev Close :  $

 

  Investor Relations > Introduction
............................................................................................................................................................................................................................................................................................................

 

 Introduction


Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative treatments for cancer, central nervous system disorders and other unmet medical needs.

Our mission is to impact the health and wellness of patients with life-threatening and life-debilitating diseases.
 

 Recent News ........... [more]
February 17, 2010
Rexahn Pharmaceuticals Provides Key Goals for 2010
February 01, 2010
Rexahn Pharmaceuticals to Present at the 12th Annual Bio CEO & Investor Conference
January 19, 2010
Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117
December 14, 2009
Rexahn and TheraTarget Form Nano Science Research Collaboration